The human p53 protein is composed of 393 amino acids and structurally resembles a transcriptional activator factor ( Fig. 1 ) (7-9). The NH2 terminus of p53 is highly acidic with a net charge that is similar to that of known transcriptional transactivators such as the VPI6 protein encoded by herpes simplex virus and the yeast GAL-4 protein. The COOH terminus is rich in basic amino acid sequences similar to that of a DNA binding domain. Last, there are three nuclear localization signals (NLS) 1 at the carboxyl terminus (10) with the predominant NLS positioned adjacent to serine 315 (serine 312 in mouse and rat p53), which is phosphorylated in vitro and in vivo by cdc-2/p34 kinase (11-13 Vol. Table 1 ). The function of wild-type and mutant p53 in tumor suppression and transformation will be described in detail in the following sections.
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specific sites in SV4O are GC rich and do not share any obvious homology with the sites identified by the immunoprecipitation method ( defective at this step or upstream from this step and fail to stabilize wild-type p53 in response to DNA damage by gamma-irradiation and fail to arrest cell growth (59). In the negative regulatory pathway the increase in wild-type p53 protein levels, through its interaction with TBP, could lead to the suppression of transcription of genes that promote cell growth, which could lead to an inhibition of cell proliferation (88). Mutant p53 proteins are deficient in suppression of transcription and therefore should not inhibit expression of growthpromoting genes that would maintain cell proliferation.
In the positive regulatory pathway, the elevated levels of wild-type p53 could result in the stimulation of transcription of genes that are involved in DNA repair and genes that negatively control cell growth, which could result in an arrest of proliferation in the GI phase of the cell cycle (59). The mdm-2 gene product is a cellular regulator of wild-type p53 function and is also positively responsive to elevated wild-type p53 proteins levels as described in the text (90; Wu, H., Bayle, Olsen and A. J. Levine, unpublished results). The increase in MDM-2 levels could negatively feedback on the increased levels of wild-type p53 in an autoregulatory loop pathway, which when in complex at the appropriate concentration could reverse the cell cycle block. Overexpression of the MDM-2 protein through amplification or deregulation of transcription, perhaps through translocation, promotes tumorigenesis (94). In addition, several of the DNA tumor virus oncogene products, such as SV4O T-antigen, adenovirus E1B-SSKd protein, and the human papilloma virus E6 gene product, inhibit wild-type p53 trans activation, and by blocking wild-type p53 function may in part promote carcinogenesis.
Other signals may also influence cell growth and tumorigenesis through a wild-type p53 intermediate by alternative pathways resulting in different phenotypes.
For example, the adenovirus E1A gene product induces apoptosis (programmed cell death) in cells that express wild-type p53 protein (100). Inhibition of wild-type p53 activity by cotransfecting EIA and E1B prevents apoptosis and results in transformation.
Last, abnormal DNA intermediates or structures may increase wild-type p53 protein levels, which results in apoptosis to eliminate the aberrant cell or arrest cell growth so that the DNA could be repaired. These mechanisms act as a safeguard against tumorigenesis.
Loss of wild-type p53 function either by mutation, complex formation with a viral oncogene product or cellular encoded negative regulator (or regulators), or alteration in subcellular localization removes this safeguard against tumorigenesis and promotes cancer. 
